X
[{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$125.0 million","newsHeadline":"Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biond Biologics Announces Closing of $15 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics to Present at the Raymond James LILRB\/ILT Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Biond Biologics
Filters
Companies By Therapeutic Area
Details:
BND-35 is a novel anti-ILT3/LILRB4 antagonist antibody, it is being developed in combination with Nivolumab for the treatment of solid tumors.
Lead Product(s):
BND-35,Nivolumab
Therapeutic Area: Oncology
Product Name: BND-35
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 24, 2024
Details:
BND-22 (SAR444881), is a humanized IgG4, antagonist antibody targeting the ILT2 receptor in development for the treatment of solid tumors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules.
Lead Product(s):
BND-22,Pembrolizumab
Therapeutic Area: Oncology
Product Name: SAR444881
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 23, 2022
Details:
BND-22 (SAR444881), a novel immune checkpoint inhibitor targeting the Immunoglobulin-like transcript receptor 2 or ILT2, enhances anti-tumor activity of T cells and NK cells.
Lead Product(s):
BND-22,Pembrolizumab ,Cetuximab
Therapeutic Area: Oncology
Product Name: BND-22
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 20, 2022
Details:
The financing has sopported the development of BND-22 (SAR444881), the company’s Ig-Like Transcript 2 (ILT2) receptor-blocking antibody, and the first patient has been dosed in the first-in-human, phase 1 clinical trial of BND22.
Lead Product(s):
BND-22,Pembrolizumab
Therapeutic Area: Oncology
Product Name: SAR444881
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Deep Insight
Deal Size: $15.0 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
November 03, 2021
Details:
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.
Lead Product(s):
BND-22
Therapeutic Area: Oncology
Product Name: BND-22
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: $1,125.0 million
Upfront Cash: $125.0 million
Deal Type: Licensing Agreement
January 12, 2021